XLV - Health Care Select Sector SPDR ETF
| Previous Close | 91.09 |
| Open | 91.30 |
| Bid | 88.10 x 1100 |
| Ask | 94.77 x 1000 |
| Day's Range | 91.25 - 91.56 |
| 52 Week Range | 78.32 - 91.79 |
| Volume | 8,144,869 |
| Avg. Volume | 7,075,492 |
| Net Assets | 16.98B |
| NAV | 88.91 |
| PE Ratio (TTM) | N/A |
| Yield | 1.41% |
| YTD Return | 8.34% |
| Beta (3y) | 1.00 |
| Expense Ratio (net) | 0.14% |
| Inception Date | 1998-12-16 |
- Investopedia•4 days ago
Investors Get Defensive With Shift to Health Care
The past week, investors have been moving money into more safe-haven sectors like health care and away from higher-risk categories. Namely, they are shifting funds from technology and financial stocks toward the health care sector, according to Bank of America Merrill Lynch’s monthly fund managers survey.
ETF Database•4 days agoETF Scorecard: August 17 Edition
To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Thursday’s open to this week’s Wednesday close.
- ETF Trends•7 days ago
Healthcare ETFs Can Continue to Impress
The Health Care Select Sector SPDR (XLV) , the largest healthcare exchange traded fund by assets, is up nearly 3% over the past month and is closing in on record highs. Some market observers are betting healthcare will reach and exceed those all-time highs. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
- Zacks•8 days ago
Health Care ETFs Outperforming: Will the Rally Last?
Health care ETFs are defensive ones, which helped those to shine amid market doldrums.
- ETF Trends•12 days ago
Investors Flocked to Healthcare ETFs in July
With the healthcare sector recently outperforming technology, investors have been embracing healthcare exchange traded funds. The Health Care Select Sector SPDR (XLV) is the largest healthcare ETF by assets. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
- MarketWatch•12 days ago
Health care ETF rises toward 9-day win streak, longest in 3 1/2 years
The health care sector continues higher, with the SPDR Health Care Select Sector ETF (xlv) on track for the longest win streak in 3 1/2 years, as it holds its lead as the best performing S&P 500 (spx) sector over the past three months. The sector ETF (XLV) edged up 0.1% toward its ninth-straight gain, which would be the longest such streak since the nine-session win streak ended Feb. 23, 2015. The next best sector-ETF performer over that time is the SPDR Consumer Discretionary Select Sector ETF (xly) which is up 9.2%, while the S&P 500 (spx) has gained 6.0% the past three months.
- ETF Trends•13 days ago
Healthcare ETFs Look to Top Tech
At the sector level, technology ETFs often receive plenty of attention, but investors should not overlook the recent out-performance offered by healthcare equivalents. For example, over the past 90 days, ...
- Investopedia•14 days ago
Why Health Care Stocks Are Outshining The Techs
Health care stocks have made a sharp break to the upside so far in the third quarter, leading the S&P 500 Index (SPX) and outpacing tech stocks in the process. As measured by both the S&P 500 Health Care Index and the Health Care Select Sector SPDR ETF ( XLV), health care stocks closed Monday just 1.8% below their record highs set in January. "Overall they look quite good," said Matt Maley, equity strategist at Miller Tabak, in an interview with CNBC.
Market Realist•14 days agoMylan Stock Trending Higher before Its Q2 2018 Results
On August 3, Mylan (MYL) stock ended the trading day at $38.45 per share, rising ~5.3% compared to the previous day’s closing price. Mylan released its Q1 2018 earnings results on May 9. Mylan is also facing some supply constraints for the EpiPen, its allergy product, due to supply delays from Pfizer (PFE).
- MarketWatch•15 days ago
Henry Schein's stock rallies after earnings and profit beat, restructuring announced
MARKET PULSE Shares of Henry Schein Inc. (hsic) rallied 3.5% in premarket trade Monday, after the health care services company beat profit and sales expectations and raised its earnings outlook, while announcing restructuring actions that include job cuts and facility closings.
- ETF Trends•18 days ago
12 U.S. Sector ETFs to Play in Case of an Escalating Trade War
If the U.S. is stuck in an escalating trade war, stocks and sector-related ETFs with the highest domestic sales exposure in the U.S. should begin to stand out. “If trade tensions continue to rise and new ...
ETF Database•18 days agoETF Scorecard: August 3 Edition
To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.
- Market Realist•19 days ago
DaVita’s Q2 2018 Earnings Surpass Analysts’ Estimates
DaVita (DVA) released its second-quarter earnings after the market closed on August 1. It surpassed Wall Street analysts’ estimates for revenues and EPS and reported non-GAAP EPS of $1.15 on revenues of $2.9 billion. The EPS estimate was $0.97 on revenues of $2.8 billion.
- Market Realist•20 days ago
Investors: What to Expect from July’s Job Growth Figures
What Will Financial Markets Look for in July's Jobs Report? For the first half of the year, the job growth has averaged 215,000—compared to 182,000 during the same period last year. The job growth in June was broad-based with the private sector adding 202,000 jobs and governments adding 11,000.
- Market Realist•21 days ago
What to Expect for DaVita’s Q2 2018 Earnings
DaVita (DVA), which divides its business into two segments, DaVita Kidney Care and DaVita Medical Group, is set to release its Q2 2018 results tomorrow. Analysts expect it to post EPS of $0.97 on revenue of $2.8 billion. The chart below shows DaVita’s EPS and revenue since Q1 2017, as well as analysts’ Q2 2018 estimates.
- Market Realist•22 days ago
What to Expect from Incyte’s Q2 2018 Earnings on July 31
Incyte (INCY) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS at $0.34 on revenues of $473.8 million in Q2 2018.
Market Realist•27 days agoJNJ Stock Rose on Strong Q2 Results: Will Momentum Continue?
On July 18, 2018, Johnson & Johnson (JNJ) closed at $127.80. The stock fell ~1% from the previous day’s closing price of $129.11. On the previous day, JNJ stock had registered a rise of ~3.5% triggered by the strong Q2 2018 earnings results. The stock is currently trading ~14% lower than its 52-week high of $148.32 reported on January 17, 2018. The stock registered a 52-week low of $118.62 on May 29, 2018, on the news that the company was scrapping a Phase Ib/II trial for Darzalex for the treatment of advanced or metastatic NSCLC (non-small cell lung cancer).
- MarketWatch•28 days ago
Pfizer to create 450 new jobs in Michigan as it builds a new sterile injectable facility
Pfizer Inc. (pfe) said Tuesday it will create 450 new jobs, as it unveiled plans to build a new $465 million sterile injectable facility in Portage, Mich. The drugmaker said the new plant is part of its previously announced plan to invest $5 billion in U.S.-based capital projects, as a result of the Tax Cuts and Jobs Act enacted this year. Pfizer currently employs 2,200 people in Portage, about 2.4% of its total workforce of 90,400 employees, according to FactSet. Pfizer's stock rallied 1%.
- Benzinga•28 days ago
A Scintillating Health Care ETF
One of the best-performing corners of the health care sector this year is the medical device and equipment space, and total returns confirm the sentiment. The two exchange traded funds dedicated to medical ...
Market Realist•29 days agoHow Johnson & Johnson’s Earnings Trended in Q2 2018
On July 17, Johnson & Johnson (JNJ) reported its Q2 2018 earnings results. JNJ stock declined ~3.6% on the day. The company registered adjusted EPS (earnings per share) of $2.10, up ~14.8% on a YoY (year-over-year) basis. The adjusted net earnings in the quarter came in at $5.7 billion, a YoY rise of ~14%.
- Investopedia•29 days ago
Top 3 Healthcare Stocks for 2018
The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.
- Investopedia•last month
Top 3 Healthcare ETFs for 2018
The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.
- CNBC Videos•14 days ago
Top technician says it might be time to make a big change...
Technician Carter Worth, Cornerstone Macro, on whether CHURT is the new FANG. With CNBC's Brian Sullivan and the Fast Money traders, Tim Seymour, David Seaburg and Guy Adami.
- CNBC Videos•19 days ago
It's time to rotate into value, says JPM's Kolanovic
JP Morgan's Marko Kolanovic sees a rotation out of growth and into value. With CNBC's Phil LeBeau and Scott Wapner, and the Fast Money traders, Pete Najarian, Karen Finerman, Steve Grasso and Guy Adami.
- CNBC Videos•20 days ago
Health care could challenge tech for market leadership
CNBC's Mike Santoli breaks down signs that health care could challenge technology for market leadership.
